贝那普利对肝纤维化大鼠ACE2和Ang-（1-7）的影响

史媛媛; 申凤俊; 杨芳

贝那普利对肝纤维化大鼠ACE2和Ang-（1-7）的影响

山西医科大学第一医院消化科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 276
- HTML全文浏览量: 26
- PDF下载量: 194
- 被引次数: 0
出版历程
- 出版日期: 2011-03-20

Effect of Benazepril on ACE2 and Ang- (1-7) of hepatic fibrosis in rats

摘要

摘要: 目的研究血管紧张素转化酶抑制剂（ACEI）贝那普利对大鼠肝纤维化模型的疗效及对肝脏血管紧张素转化酶2（ACE2）和血管紧张素-（1-7）[Ang-（1-7）]的影响。方法制备四氯化碳（CCl4）诱导的大鼠肝纤维化模型,同时应用贝那普利灌胃,共8周。测定各组门脉压力,对肝组织进行常规HE及Masson三色染色,免疫组织化学染色ACE2,酶联免疫法测定Ang-（1-7）水平。结果贝那普利可明显改善肝纤维化的程度,降低门脉压力（P<0.05）,并可增加血浆Ang-（1-7）水平（P<0.01）。结论贝那普利具有良好的抗肝纤维化作用,可能与增加Ang-（1-7）有关。
- 肝硬化 /
- 血管紧张素类 /
- 血管紧张素转换酶抑制药 /
- 贝那普利
Abstract: Objective To explore the protective effects of angiotensin converting enzyme inhibitors benazepril on hepatic fibrosis induced by chronic carbon tetrachloride (CCl4) in rats and to observe the effect on angiotensin converting enzyme2 (ACE2) and angiotensin- (1-7) [Ang- (1-7) ] on the liver.Methods Except rats in control group, all were given intraperitoneal injections of 40 % CCl4, and from the first day of the intraperitoneal injection, rats in treatment group were given benazepril for 8 weeks by gastric gavage.Liver tissue and blood samples of all the rats were examined at the end of 8 weeks.Portal pressure was measured and histopathological study of the liver tissue was done with hematoxylin-eosin (HE) and Masson trichrome staining.ACE2 were evaluated by immunohistochemistry.Ang- (1-7) levels were determined by enzyme-linked immunosorbent assay (ELISA) .Results Benazepril significantly attenuated the degree of hepatic fibrosis, reduced portal pressure (P<0.05) and elevated plasma Ang- (1-7) level (P<0.05) .Conclusion Benazepril can delay the progression of hepatic fibrosis.It's probably relative to increase Ang- (1-7) level.
- liver cirrhosis /
- angiotensins /
- angiotensin-converting enzyme inhibitors /
- Benazepril

HTML全文

参考文献(14)

[1]申凤俊, 阴赪宏, 王宝恩.肾素血管紧张素系统与肝纤维化、肝硬化[J].中华肝脏病杂志, 2003, 11 (7) :447-448.

[2]邵颖, 陆利民.ACE2-RAS代谢新通路在心血管活动调解中的作用[J].心血管病学进展, 2005, 26 (5) :550-553.

[3]中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) :324-329.

[4]申凤俊, 朱跃科, 贾继东, 等.缬沙坦抗大鼠肝纤维化疗效及机制的研究[J].中华肝脏病杂志, 2004, 12 (10) :605-608.

[5]Schindler C, Bramlage P, Kirch W, et al.Role of the vasodilator peptide angiotensin- (1-7) in cardiovascular drug therapy[J].Vasc Health Risk Manag, 2007, 3 (1) :125-137.

[6]Lubel JS, Herath CB, Burrell LM, et al.Liver disease and the renin-angiotensin system:Recent discoveries and clinical implications[J].J Gastroenterol Hepatol, 2008, 23 (9) :1327-1338.

[7]Herath CB, Warner FJ, Lubel JS, et al.Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin- (1-7) levels in experimental biliary fibrosis[J].J Hepatology, 2007, 47 (3) :387-395.

[8]Huang ML, Li X, Meng Y, et al.Upregulation of an-gio-tensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors[J].Cli Exp Pharmacol Physiol, 2010, 37 (1) :e1-6.

[9]Lubel JS, Herath CB, Tchongue J, et al.Angiotensin- (1-7) , an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat[J].Clinical Sci (Lond) , 2009, 117 (11) :375-386.

[10]Herath CB, Lubel JS, Jia Z, et al.Hepatic angiotensin- (1-7) production and portal pressure[J].Am J Physiol Gastrointest Liver Physiol, 2009, 297 (1) :G98-106.

[11]Lambert DW, Hooper NM, Turner AJ.Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system[J].Biochemical Pharmacology, 2008, 75 (4) :781-786.

[12]潘伟男, 封芬, 陈峰.肾素-血管紧张素系统的新认识[J].中国心血管病研究杂志, 2006, 4 (10) :782-784.

[13]Iwata M, Cowling RT, Gurantz D, et al.Angiotensin- (1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects[J].Am J Physiol Heart Circ Physiol, 2005, 289 (6) :H2356-2363.

[14]Rockey DC.Vasoactive agents in intrahepatic portal hypertension and fibrogenesis:implications for therapy[J].Gastroenterology, 2000, 118 (6) :1261-1265.

施引文献

资源附件(0)

访问统计